Biocardia 

Biocardia 

Yahoo Finance • 24 days ago

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corp... Full story

Yahoo Finance • last month

Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight

The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease... Full story

Yahoo Finance • 3 months ago

Pre-Market Movers: TNGX, WOK, GOCO Set The Path

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story

Yahoo Finance • 3 months ago

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

BioCardia: FDA Says CardiAMP HF II May PMA For Cell Therapy In Ischemic HFrEF; Stock Up

(RTTNews) - BioCardia, Inc. (BCDA) announced that the U.S. FDA has confirmed the company's pivotal Phase 3 CardiAMP Heart Failure II (HF II) trial may serve as the basis for a Premarket Approval (PMA) application for its CardiAMP Cell Ther... Full story

Yahoo Finance • 4 months ago

BioCardia Aligns With FDA On Helix Transendocardial Delivery Catheter Marketing Pathways

(RTTNews) - BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Friday announced alignment with the U.S. food and drug administration after a pre-submission meeting on the Helix transendocardial delivery catheter syst... Full story

Yahoo Finance • 5 months ago

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a cor... Full story

Yahoo Finance • 5 months ago

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted... Full story

Yahoo Finance • 9 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participat... Full story

Yahoo Finance • 9 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of... Full story

Yahoo Finance • 10 months ago

BioCardia, Inc. Q3 Loss Decreases, Beats Estimates

(RTTNews) - BioCardia, Inc. (BCDA) released Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's earnings came in at -$1.48 million, or -$0.24 per share. This compares with -$... Full story

Yahoo Finance • 10 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for t... Full story

Yahoo Finance • 10 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corp... Full story

Yahoo Finance • 10 months ago

BioCardia Inc. (BCDA): 2025 Product Pipeline and Strategy Analysis Report

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "BioCardia Inc. (BCDA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. BioCardia Inc is at the forefront of regenerative medicine, focusing on... Full story

Yahoo Finance • 11 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance w... Full story

Yahoo Finance • 11 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today... Full story

Yahoo Finance • 11 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint... Full story

Yahoo Finance • 12 months ago

Notable Wednesday Option Activity: CLSK, BKD, AVXL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CleanSpark Inc (Symbol: CLSK), where a total volume of 108,050 contracts has been traded thus far today, a contract volum... Full story

Yahoo Finance • 12 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s Pr... Full story

Yahoo Finance • last year

BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025

Earnings Call Insights: BioCardia, Inc. (BCDA) Q2 2025 MANAGEMENT VIEW * Peter A. Altman, President and CEO, reported the completion of the CardiAMP Heart Failure trial and noted its primary outcomes were presented as a late-breaking c... Full story